An atypical addition to the chemokine receptor nomenclature: IUPHAR Review 15

Authors

  • Françoise Bachelerie,

    1. INSERM UMR-S996, Laboratory of Excellence in Research on Medication and Innovative Therapeutics, Université Paris-Sud, Clamart, France
    Search for more papers by this author
  • Gerard J Graham,

    Corresponding author
    1. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK
    • Correspondence

      Gerard J. Graham, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK. E-mail: gerard.graham@glasgow.ac.uk

    Search for more papers by this author
  • Massimo Locati,

    1. Department of Molecular Biotechnology and Translational Medicine, University of Milan, Milan, Italy
    2. Istituto Clinico Humanitas, Humanitas University, Milano, Italy
    Search for more papers by this author
  • Alberto Mantovani,

    1. Department of Molecular Biotechnology and Translational Medicine, University of Milan, Milan, Italy
    2. Istituto Clinico Humanitas, Humanitas University, Milano, Italy
    Search for more papers by this author
  • Philip M Murphy,

    1. Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
    Search for more papers by this author
  • Robert Nibbs,

    1. Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, UK
    Search for more papers by this author
  • Antal Rot,

    1. Medical Research Council Centre for Immune Regulation, Institute of Biomedical Research, School of Infection and Immunity, University of Birmingham, Birmingham, UK
    Search for more papers by this author
  • Silvano Sozzani,

    1. Istituto Clinico Humanitas, Humanitas University, Milano, Italy
    2. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
    Search for more papers by this author
  • Marcus Thelen

    1. Institute for Research in Biomedicine, Bellinzona, Switzerland
    Search for more papers by this author

  • The authors are listed in alphabetical order and are members of the Chemokine Receptor Nomenclature Subcommittee, Nomenclature Committee for Receptors and Ion Channels, International Union of Pharmacology.

Abstract

Chemokines and their receptors are essential regulators of in vivo leukocyte migration and, some years ago, a systematic nomenclature system was developed for the chemokine receptor family. Chemokine receptor biology and biochemistry was recently extensively reviewed. In this review, we also highlighted a new component to the nomenclature system that incorporates receptors previously known as ‘scavenging’, or ‘decoy’, chemokine receptors on the basis of their lack of classical signalling responses to ligand binding and their general ability to scavenge, or sequester, their cognate chemokine ligands. These molecules are now collectively referred to as ‘atypical chemokine receptors’, or ACKRs, and play fundamental roles in regulating in vivo responses to chemokines. This commentary highlights this new addition to the chemokine receptor nomenclature system and provides brief information on the four receptors currently covered by this nomenclature.

Ancillary